The value of the BIOCHIP mosaic-based indirect immunofluorescence technique in the diagnosis of pemphigus and bullous pemphigoid in Turkish patients by Birgül Özkesici et al.
202 ACTA DERMATOVENEROLOGICA CROATICA
Acta Dermatovenerol Croat                                 2017;25(3):202-209                       CliniCAl ArtiCle
The Value of the BIOCHIP Mosaic-based Indirect  
Immunofluorescence Technique in the Diagnosis of 
Pemphigus and Bullous Pemphigoid in Turkish Patients
Birgül Özkesici1, Derya Mutlu2, Levent Dönmez3, Soner Uzun1
1Department of Dermatology, Akdeniz University Faculty of Medicine, Antalya, Tur-
key; 2Department of Microbiology-Clinical Microbiology, Akdeniz University Faculty of 
Medicine, Antalya, Turkey; 3Department of Public Health, Akdeniz University Faculty of 
Medicine, Antalya, Turkey
ABSTRACT Autoimmune bullous diseases (ABD) are a rarely seen 
group of diseases, of which pemphigus and bullous pemphigoid (BP) 
are the major groups. Diagnosis is generally based on the combina-
tion of clinical features, histopathologic and immunofluorescence 
(iF) findings, and/or enzyme-linked immunosorbent assay (eliSA). 
Aims of the work were to determine the value of the innovative BiO-
CHiP mosaic-based indirect iF technique in the diagnosis of pemphi-
gus and BP in turkish patients. A total of 63 patients (45 pemphigus 
and 18 BP) in the active phase of the disease alongside 35 healthy 
controls were included in the study. All sera from patients and con-
trols were tested using the BiOCHiP technique, and the results were 
compared with direct iF and/or eliSA. the sensitivity and specificity 
of this new technique were calculated for validity. the sensitivity and 
specificity of BiOCHiP in the diagnosis of pemphigus was found to 
be 91.1% and 97.1%, respectively. in detection of anti-Dsg1 and anti-
Dsg3 autoantibodies, the correlation between BiOCHiP and eliSA 
was statistically significant (P<0.01). the sensitivity and specificity of 
BiOCHiP in the diagnosis of BP was found to be 94.4% and 94.3%, re-
spectively. in detection of anti-BP180 autoantibodies, the correlation 
between the BiOCHiP and eliSA was statistically significant (P<0.01). 
the main limitations are the relatively low number of samples and 
testing with only one dilution. Direct iF was not performed in all pa-
tients, and the low rate of DiF positivity also can be a bias in compari-
son with BiOCHiP. the new BiOCHiP technique is a highly sensitive 
and specific tool in the diagnosis of pemphigus and BP.
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INTRODUCTION
Autoimmune bullous diseases (ABD) are poten-
tially life threatening diseases characterized by au-
toantibodies formed against the structural proteins 
of the epidermis or the dermal-epidermal junction 
(1-3). Currently, demonstration of such antibodies is 
the gold standard in the diagnosis of this group of 
diseases. the methods that are used for this purpose 
are: direct immunofluorescence (DiF), indirect im-
203ACTA DERMATOVENEROLOGICA CROATICA
munofluorescence (iiF), enzyme-linked immunosor-
bent assay (eliSA), immunoprecipitation and immu-
noblotting (4,5). in routine examinations, DiF is the 
most commonly used among these tests. Although 
it is noted to be quite sensitive in reported studies, 
this sensitivity can show variability depending on the 
centers in which it is performed. Similarly, eliSA is 
highly sensitive and specific in the diagnosis of this 
group of diseases. the most important advantage of 
eliSA is determining antibody titers as a quantitative 
test (6). in recent years, the BiOCHiP mosaic-based 
iiF technique has been developed as a new method 
for the routine diagnosis of ABD (7-11). the presence 
of multiple antigenic structures on a BiOCHiP slide 
enables a differential diagnosis among the ABD sub-
types from a single serum sample.
in this study, our goal was to determine the value 
of this new method in the diagnosis of pemphigus 
and bullous pemphigoid (BP) by using the BiOCHiP 
mosaic-based iiF technique. in addition, we also eval-
uated whether the BiOCHiP technique is compatible 
or not with those routine diagnostic methods that are 
currently accepted as the gold standard diagnostic 
tools for this group of diseases. 
PATIENTS AND METHODS 
Patients 
in this study, a total of 63 patients (45 with pem-
phigus and 18 with BP) in the active phase of the dis-
ease were included, alongside 35 healthy controls. 
the study was conducted prospectively. Healthy 
volunteers with autoimmune diseases and under im-
munosuppressive treatment were not included in the 
control group. the patients in the active phase of the 
disease, either at first presentation or with relapse, 
were included the study. the histopathologic exami-
nation of all patients was compatible with pemphi-
gus or BP, and the diagnosis of pemphigus or BP was 
confirmed by DiF and/or eliSA tests. DiF was not per-
formed if histopathology reports from another cen-
ter were compatible with pemphigus and BP and the 
diagnosis confirmed by eliSA. the clinical features of 
patients, DiF findings, anti-Dsg1, anti-Dsg3, and anti-
BP180 autoantibody titers were recorded by eliSA. 
Sera from all patients and controls were stored at 
-20°C and then tested by the BiOCHiP mosaic-based 
iiF technique. this study was approved by the ethical 
Committee of Akdeniz University, and informed con-
sent was obtained from each of the contributors. 
The BIOCHIP mosaic-based IIF technique
Anti-skin antibody detection by iiF was performed 
on the BiOCHiP Dermatology Mosaic 7 (eUrOiMMUn, 
lübeck, Germany) according to the manufacturer’s 
instructions. this test is designed exclusively for the 
in-vitro determination of human antibodies in serum. 
in this approach, the substrates are no longer applied 
directly to microscope slides, but initially to thin glass 
slides. the millimeter-sized fragments, which are cut 
mechanically, are named BiOCHiPs. the BiOCHiPs 
were then glued onto microscope slides using auto-
mated assembly equipment. the miniature size of the 
BiOCHiPs means that the reaction fields of the slides 
can be supplemented with further BiOCHiP sub-
strates if required (8) (this is referred to as the BiOCHiP 
Mosaic). ten incubation fields exist on one standard-
sized slide (each incubation field is for one of the pa-
tients), and each field is a mosaic of six different anti-
genic structures as a substrate. in this study, the sub-
strates were: sections of primate monkey esophagus, 
primate (1 mol/l naCl) salt-split skin (SSS) section, eU 
90 cells transfected with the Dsg1, Dsg3, and C-ter-
minal globular domain of BP230, and recombinant 
tetrameric BP180-nC16A-4X spots. the substrates 
were incubated with the sera of the patients and 
controls at a dilution of 1/10 in PBS-tween at room 
temperature for 30 minutes. this constitutes the first 
incubation, allowing the antibodies to bind to the 
antigens on the BiOCHiP slide. After that, the slides 
were rinsed with a flush of PBS-tween and immersed 
in PBS-tween for 5 minutes. in the second incubation 
period, the attached antibodies were stained with flu-
orescein-labeled anti-human antibodies (FitC) in the 
dark at room temperature for a period of 30 minutes. 
then, the slides were washed in the dark as described 
previously and evaluated visually by immunofluores-
cence microscopy. the sera of the patients and con-
trols were blind-evaluated by the researcher on the 
same slide. the results were compared with the posi-
tive control sera of pemphigus and BP.
Diagnosis of pemphigus was established on the 
detection of intercellular staining (iCS) on the mon-
key esophagus and/or anti-Dsg1 and/or anti-Dsg3 
autoantibodies using the BiOCHiP technique. Diag-
nosis of BP was established on the detection of the 
epidermal or epidermal and dermal deposition on 
SSS, and/or anti-BP180 and/or anti-BP230 autoanti-
bodies also using the BiOCHiP technique.
ELISA test
For the detection of anti-Dsg1 and anti-Dsg3 an-
tibodies, sera from the patients and control group 
were studied with a commercially available eliSA 
kit (eUrOiMMUn, lübeck, Germany) according to 
the manufacturers’ instructions. Antigens coated on 
wells were an extracellular domain of Dsg1 (5 subdo-
mains) and Dsg3 (5 subdomains) proteins produced 
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recombinantly in mammalian cells for anti-Dsg1 and 
anti-Dsg3 tests, respectively. For the detection of anti-
BP180 antibodies, eliSA plates coated with immuno-
genic tetramer of nC16A domain (BP180) that are ex-
pressed in Escherichia coli were used (eUrOiMMUn, 
lübeck, Germany). For each test, three calibrators, 
containing the 2, 20, and 200 rU/ml analyte, as well 
as a positive and a negative control, were included in 
each run. Analyte concentrations in the samples of 
patients and controls were calculated in rU/ml using 
curves formed by calibrators. the concentrations be-
low the 20 rU/ml were considered negative for the 
Dsg1, Dsg3, and BP180 tests. While concentrations 
between 20 and 200 rU/ml were quantified, any con-
centrations above 200 rU/ml were merely reported 
as being “above 200 rU/ml”.
Statistical analyses 
Statistical analyses were performed with SPSS 
(version 22.0). to detect the diagnostic value of the 
BiOCHiP technique, the results were compared with 
the results of the gold standard methods – the DiF 
and/or eliSA test – for validity; the sensitivity and 
the specificity values were calculated. Kappa values 
were calculated to measure the level of correlation 
(consistency) between the two methods. Kappa was 
obtained by the purification of the consistency due 
to chance from observed consistency:
Kappa = (observed consistency – consistency due 
to chance) / (1 – consistency due to chance)
results were expressed as mean ± Standard De-
viation. in all analyses, P<0.05 was considered statisti-
cally significant. While comparing the averages of the 
autoantibody titers obtained using the eliSA test, the 
Mann-Whitney U test was used, the non-parametric 
equivalent of the t-test, because of the high vari-
ance.  
RESULTS 
Data of patients with pemphigus 
twenty nine newly diagnosed and 16 relapsed pa-
tients with pemphigus and 35 individuals (17 women 
and 18 men) in the control group were included in 
the study. the demographic features of the patients 
and control group are shown in table 1.  
the mean duration after onset of disease of the 
newly diagnosed patients with pemphigus was 
295.93±125.87 (mean ± Standard Deviation) days, 
while in patients with relapse it was 1360.37±169.46 
days. Subtypes of pemphigus in the study group were 
pemphigus vulgaris (PV) (n=39), pemphigus foliaceus 
(PF) (n=3), pemphigus herpetiformis (PH) (n=1), igA 
pemphigus (igAP) (n=1) and pemphigus vegetans 
(PVe) (n=1). the mean age of the patients at onset 
of disease was 46.35±12.21 years. Mucosal involve-
ments of the various sites were observed in 66.7% 
Table 1. Demographic and clinical data of the patients in the pemphigus, bullous pemphigoid (BP), and 
control groups 


























































Ozkesici et al. Acta Dermatovenerol Croat
BiOCHiP in diagnosis of pemphigus and bullous pemphigoid   2017;25(3):202-209
ACTA DERMATOVENEROLOGICA CROATICA
of the patients. Oral mucosa was the most common 
mucosal involvement, which was observed in 80.0% 
of the patients (table 1).
Results of the BIOCHIP technique
the sera of 45 patients whose diagnoses were con-
firmed by DiF and/or eliSA were tested using the BiO-
CHiP technique. BiOCHiP was positive for pemphigus 
with at least one substrate in 41 of the patients. in the 
control group, BiOCHiP was positive in only 1 (2.9%) 
serum (false positivity). the sensitivity and specificity 
of BiOCHiP in the diagnosis of pemphigus was found 
to be 91.1% and 97.1%, respectively (table 2).
Table 2. the sensitivity and specificity of the BiOCHiP technique in the diagnosis of pemphigus
BIOCHIP results  DIF and/or ELISA results     Total
Positive % Negative % n %
Positive 41 91.1* 1 2.9 42 52.5
Negative 4 8.9 34 97.1** 38 47.5
Total 45 100.0 35 100.0 80 100.0
*Sensitivity; **Specificity
Table 3. the correlation between the BiOCHiP 
technique and direct immunofluorescence (DiF) 
in detection of intracellular cytokine staining 
(iCS) 
DIF-ICS
BIOCHIP-ICS Positive Negative Total
Positive 13 11 24
Negative 6 7 13
Total 19 18 37
Correlation = 0.5405; Kappa = 0.076; P=0.642
Table 4. the correlation between the BiOCHiP 
technique and enzyme-linked immunosorbent 
assay (eliSA) in the detection of anti-Dsg1 auto-
antibodies
BIOCHIP
ELISA Positive Negative Total
Positive 15 10 25
Negative 2 53 55
Total 17 63 80
Correlation = 0.8500; Kappa = 0.538; P<0.01
Figure 1. the sensitivity and specificity of the BiOCHiP 
technique in the diagnosis of pemphigus with intercellular 
staining (iCS), anti-Dsg1, and/or anti-Dsg3 positivity
Table 5. the correlation between the BiOCHiP 
technique and enzyme-linked immunosorbent 
assay (eliSA) in the detection of anti-Dsg3 auto-
antibodies
BIOCHIP
ELISA Positive Negative Total
Positive 37 2 39
Negative 3 38 41
Total 40 40 80
Correlation = 0.9375; Kappa = 0.659; P<0.01
A DiF examination was performed on 37 of the 
45 patients, and 19 (51.4%) were positive. Since his-
topathological examination of 8 patients were re-
ported as pemphigus, the biopsy for DiF examination 
was not taken again. DiF was not performed and the 
diagnosis was confirmed by eliSA in these patients. 
iCS staining on the monkey esophagus sections was 
observed in 31 (68.9%) patients with BiOCHiP. in 
detection of iCS staining, no statistically significant 
correlation was observed between BiOCHiP and DiF 
(table 3). the specificity of iCS staining on esophagus 
section with BiOCHiP was 100% (Fig. 1). 
eliSA was performed on the patients with pem-
phigus (n=45) and the control group (n=35): the 
anti-Dsg1 and anti-Dsg3 autoantibodies of the entire 
control group were found to be negative. the anti-
Dsg1 autoantibodies in 25 patients and the anti-Dsg3 
autoantibodies in 39 patients with pemphigus were 
positive in eliSA. BiOCHiP found anti-Dsg1 positivity 
in 17 patients, anti-Dsg3 in 39 patients with pemphi-
gus. the sensitivity and specificity of BiOCHiP in de-
tecting autoantibodies against Dsg1 in patients with 
pemphigus were 37.8% and 100%, respectively, and 
against Dsg3 were 86.7% and 97.1%, respectively (Fig-
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ure 1). the correlation between BiOCHiP and eliSA in 
the detection of anti-Dsg1 and Dsg3 was statistically 
significant (table 4, table 5).
in this study, the mean value of the anti-Dsg1 au-
toantibody titers obtained by eliSA was 132.12±72.79 
rU/ml in the 17 patients with pemphigus whose anti-
Dsg1 autoantibodies were positive in BiOCHiP. On 
the other hand, the mean value of the anti-Dsg1 au-
toantibody titers obtained by eliSA was 38.29±67.06 
rU/ml in the 28 patients with pemphigus whose 
anti-Dsg1 autoantibodies were negative in BiOCHiP. 
the mean value of the anti-Dsg1 autoantibody titers 
detected by eliSA in the patients with pemphigus 
whose anti-Dsg1 autoantibody was positive in the 
BiOCHiP technique was significantly higher than in 
negative patients, and was statistically significant 
(P<0.001). Considering the similar relationship in 
anti-Dsg3 autoantibodies, the mean value of the 
anti-Dsg3 autoantibody titers obtained by eliSA was 
166.74±55.91 rU/ml in the 39 patients with pemphi-
gus whose anti-Dsg3 autoantibodies were positive 
in BiOCHiP. the mean anti-Dsg3 autoantibody titers 
obtained by eliSA were 66.67±103.28 rU/ml in the 6 
patients with pemphigus whose anti-Dsg3 autoanti-
bodies were negative in BiOCHiP. the mean value of 
the anti-Dsg3 autoantibody titers detected by eliSA 
in the patients with pemphigus whose anti-Dsg3 
autoantibodies positive in BiOCHiP was higher than 
negative patients. However, this difference was not 
statistically significant (P=0.063).
Data of patients with BP
Sixteen newly diagnosed and 2 relapsed patients 
with BP, a total of 18, were included in the study. the 
demographic features of the patients and the control 
group are shown in table 1. the mean duration after 
onset of disease for the newly diagnosed patients with 
BP was 196.5±169.46 days, while disease duration of 
the relapsed patients with BP was 1382.5±479.33 
days. the mean age at onset of BP was found to be 
56.89±24.07 years. 
Results of the BIOCHIP technique
the sensitivity and specificity of BiOCHiP in the 
diagnosis of BP was found to be 94.4% and 94.3%, re-
spectively (table 6, Figure 2).
DiF was performed on 16 of the 18 patients with 
BP. it was positive as linear igG/C3 deposition along 
the BMZ in 11 of the 16 patients. Since histopatho-
logical examinations of 2 patients were reported as 
BP, the diagnosis was confirmed by eliSA in these pa-
tients. BiOCHiP was found to be positive on SSS sec-
tions as epidermal side depositions for 15 of the 18 
patients. in 2 sera in the control group, both dermal 
and epidermal side depositions were found by BiO-
CHiP on SSS sections. Anti-BP230 was also positive in 
one of these patients. linear BMZ depositions were 
observed on the primate esophagus sections in 6 of 
the SSS-positive patients. the sensitivity and specific-
ity of the SSS substrate of BiOCHiP for the diagnosis 
of BP was 83.3% and 94.3%, respectively.
eliSA was performed on 18 patients with BP and 
35 controls. Anti-BP180 autoantibodies were positive 
in 15 of the patients with BP. these antibodies were 
negative in the control group. BiOCHiP was positive 
for purified antigen BP180 nC16A substrate in 16 of 
the patients. On the other hand, BiOCHiP was positive 
for the C-terminal globular domain of BP230 trans-
fected eU 90 cells as substrate in 12 patients with BP. 
Table 6. the sensitivity and specificity of the BiOCHiP technique in the diagnosis of bullous pemphigoid 
(BP)
BIOCHIP results DIF and/or ELISA results Total
Positive % Negative % n %
Positive 17 94.4* 2 5.7 19 35.8
Negative 1 5.6 33 94.3** 34 64.2
Total 18 100.0 35 100.0 53 100.0
*Sensitivity; **Specificity; DiF: direct immunofluorescence; eliSA: enzyme-linked immunosorbent assay
Figure 2. the sensitivity and specificity of the BiOCHiP 
technique in the diagnosis of BP with salt-split skin (SSS), 
anti-BP180 and/or anti-BP230 positivity
Ozkesici et al. Acta Dermatovenerol Croat
BiOCHiP in diagnosis of pemphigus and bullous pemphigoid   2017;25(3):202-209
207ACTA DERMATOVENEROLOGICA CROATICA
the sensitivity and specificity of BiOCHiP in detecting 
anti-BP180 autoantibodies was found to be 88.9% 
and 100%, respectively, and in detecting anti-BP230 
autoantibodies it was 66.7% and 97.1%, respectively. 
the correlation between the BiOCHiP technique and 
eliSA in the detection of anti-BP180 autoantibod-
ies was considered statistically significant (P<0.01) 
(table 7).
DISCUSSION
We found that the BiOCHiP technique was highly 
sensitive and specific in the diagnosis of both pem-
phigus and BP. Other studies have investigated the 
sensitivity and specificity of the BiOCHiP technique in 
the diagnosis of pemphigus. their results are shown 
in table 8. Van Beek et al. studied BiOCHiP in the di-
agnosis of 65 patients with PV and 50 with PF and 
observed iCS positivity with sensitivity of 100% and 
98%, respectively (9). On the other hand, iCS positivi-
ty with BiOCHiP was reported as 83% for PV in a study 
by tampoia et al. (19). the specificity of iCS positivity 
by BiOCHiP in our study was found to be 100%. this 
rate was reported as between 89% to 96% in previous 
studies (9,10). 
the sensitivity of detection of anti-Dsg3 autoan-
tibodies (87%) was higher than anti-Dsg1 (38%) in 
this study (Figure 1). Van Beek et al. reported the BiO-
CHiP sensitivity for anti-Dsg1 in the diagnosis of PV 
and PF as 52% and 90%, respectively (9). Anti-Dsg1 
antibodies diagnosed pemphigus by BiOCHiP with 
100% specificity in this study. On the other hand, the 
BiOCHiP sensitivity and specificity of anti-Dsg3 anti-
bodies in the diagnosis of PV was reported as 98.5% 
and 99.6%, respectively. Similarly, tampoia et al. re-
ported the sensitivity of anti-Dsg3 autoantibodies 
by BiOCHiP as 100%. But the sensitivity of anti-Dsg1 
antibodies, in relation to their presence in a minority 
of the patients with PV, was reported as lower by BiO-
CHiP, at 33%. they reported the specificity of the anti-
Dsg1 and anti-Dsg3 autoantibodies in the PV diagno-
sis as 98.5% and 100%, respectively. As a result they 
found that, in terms of detecting the anti-Dsg3 auto-
antibodies, BiOCHiP and eliSA methods displayed a 
strong correlation (10). russo et al. also reported that 
BiOCHiP displayed high sensitivity in the diagnosis of 
PV (97.6%) and specificity (100%) in detecting anti-
Dsg3 autoantibodies (11) (table 8).
in our study, the mean titer of anti-Dsg1 de-
tected by eliSA in patients with pemphigus whose 
anti-Dsg1 was positive in BiOCHiP was higher than 
BiOCHiP-negative patients; this was found to be sta-
tistically significant (P<0.001). Although a similar rela-
tionship was observed between anti-Dsg3-eliSA and 
anti-Dsg3-BiOCHiP, it was not statistically significant 
(P=0.063). 
We found that the sensitivity of SSS substrate in 
the diagnosis of BP by BiOCHiP was 83.3%. Damoi-
seaux et al. reported SSS sensitivity with 1/10 and/or 
1/100 dilution as 95%. the significant portion of the 
positivity was in the 1/100 dilution (7). However, since 
Table 8. Studies on the sensitivity and specificity of the BiOCHiP technique in the diagnosis of pemphigus
Studies Patients (n) iCS Anti-Dsg1 Anti-Dsg3
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
















tampoia et al. (10) PV (n: 36) %83.3 %95.5 %33.3 %98.5 %100.0 %100.0
russo et al. (11) PV (n: 42) - - %19.0 %100.0 %97.6 %100.0




igA P (n: 1)
PH (n: 1)
%68.9 %100.0 %37.8 %100.0 %86.7 %97.1
PV: pemphigus vulgaris; PF: pemphigus foliaceus; PH: pemphigus herpetiformis; igAP: igA pemphigus; PVe: pemphigus 
vegetans
Table 7. the correlation between the BiOCHiP 
technique and enzyme-linked immunosorbent 
assay (eliSA) in the detection of anti-BP180 au-
toantibodies
BIOCHIP-anti-BP180
ELISA-anti-BP180 Positive Negative Total
Positive 15 0 15
Negative 1 37 38
Total 16 37 53
Correlation = 0.9811; Kappa = 0.691; P<0.01
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Van Beek et al. conducted their study at 6 different 
dilutions, minimizing the prozone effect as a conse-
quence, the sensitivity of BMZ reactivity was found 
to be higher (98.8%) than in the previous studies and 
the current study (table 9). 
BiOCHiP is more sensitive in the diagnosis of BP 
via the detecting of anti-BP180 than anti-BP230 auto-
antibodies and SSS positivity in most of the previous 
reports (7-10). in these studies, the specificities of SSS 
section, BP180 nC16A, and the C-terminal globular 
domain of BP230 transfected cells as substrates in 
BiOCHiP technique was over 95% in the diagnosis 
of BP (table 9). Haik et al. reported that anti-BP180 
autoantibodies were undetectable by BiOCHiP in 3 
patients whose anti-BP180-eliSA titers were low (8). 
Similarly, in the current study, anti-BP180 autoanti-
bodies were undetectable by BiOCHiP in 2 patients 
whose eliSA was negative. 
CONCLUSION
this study has shown that the BiOCHiP technique 
is a valuable screening test in the diagnosis of both 
pemphigus and BP with a high degree of sensitivity 
and specificity in the turkish population with differ-
ent genetic backgrounds. it appears that the most 
sensitive substrates for the diagnosis of pemphigus 
and BP were transfected cells with Dsg3 and BP180 
nC16A, respectively. BiOCHiP may serve as a less 
time-consuming screening test in the differential di-
agnosis of ABD. However, the relatively low number 
of samples and testing with only one dilution are the 
main limitations of the study. Another limitation is 
that DiF was not performed in all patients, and the 
low rate of DiF positivity also can be a bias in com-
parison with BiOCHiP. Although BiOCHiP seems to be 
highly sensitive and specific for pemphigus and BP, 
the value of this innovative technique should also be 
evaluated for the diagnosis of other ABD. 
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